EAM
FATE icon

Eagle Asset Management’s Fate Therapeutics FATE Stock Holding History

Eagle Asset Management’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-376,460
Closed -$3.83M – 553
2022
Q4 		$3.83M Buy
376,460
+8,023
+2% +$151K 0.02% 374
2022
Q3 		$8.26M Buy
368,437
+135,735
+58% +$3.92M 0.05% 262
2022
Q2 		$5.77M Buy
232,702
+5,126
+2% +$141K 0.04% 330
2022
Q1 		$8.82M Buy
227,576
+12,232
+6% +$474K 0.05% 293
2021
Q4 		$12.9M Sell
215,344
-43,792
-17% -$2.48M 0.06% 263
2021
Q3 		$15.4M Sell
259,136
-13,630
-5% -$1.07M 0.07% 244
2021
Q2 		$23.7M Sell
272,766
-14,529
-5% -$1.17M 0.1% 220
2021
Q1 		$23.5M Buy
+287,295
New +$27.5M 0.1% 226

Other funds holding FATE

State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

Eagle Asset Management's FATE Position: Q1 2023 in Review

Eagle Asset Management sold out of Fate Therapeutics (FATE) in Q1 2023, closing a stake of 376,460 shares — an estimated $3.83M sold.

Eagle Asset Management first reported a position in FATE in Q1 2021 and held it in 8 quarters. The position peaked at $23.7M in Q2 2021. 181 funds tracked by Wall St. Rank hold FATE as of Q1 2023.

  • Eagle Asset Management reported no remaining Fate Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Eagle Asset Management sold 376,460 Fate Therapeutics shares in Q1 2023, an estimated $3.83M.
  • Eagle Asset Management first reported a position in Fate Therapeutics in Q1 2021 and held it in 8 quarters.
  • Eagle Asset Management's Fate Therapeutics position peaked at $23.7M in Q2 2021.
  • 181 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2023.

Based on Eagle Asset Management's 13F filing for Q1 2023, filed 8 May 2023.